CTLA4 and neoplasm: Treg cell depletion has shown promising results in preclinical cancer models, and anti-CTLA-4 therapy not only increases tumor-specific effector CD4+ T cells but also depletes intratumoral CTLA-4+ Tregs (98, 124).